Cell Pathways: Kommt jetzt der Rebound? - 500 Beiträge pro Seite

[Broker2010]

Nachdem Cell Pathways vor zwei Wochen um mehr als 60 % abgestürzt war, haben wir gestern einen Kurssprung von +28% gesehen.Ist das erst der Anfang des Anstiegs oder bleibt der Wert auf dem jetzigen Niveau?
Was meint Ihr?

[Plaste]

Hallo B,
ich hab mir schon einige Stücke zugelegt.
Wie war die Meldung noch mal:

Die Aktien von Cell Pathways Inc.(NasdaqNM:CLPA, WKN: 917206) notieren aktuell beinahe um zwei Drittel niedriger als noch am Ende der letzten Woche. Grund dafür
ist eine Ablehnung der FDA für das führende Medikament des Unternehmens – Aptosyn.
Nach Aussagen der Behörde könne man dem Genehmigungsantrag auf Grund von noch nicht näher spezifizieren „Defiziten“ im für die Zulassung nötigen Antrag
zustimmen.
Aptosyn soll der Behandlung von adenomatous polyposis dienen. Einem Zustand in welchem Patienten zur Bildung von Polypen im Darm neigen, die eine erhebliche
Krebsgefahr darstellen.

Der Chief Executive gab in einer Stellungnahmen bekannt, dass er dem Genehmigungsverfahren weiter zuversichtlich entgegensieht. Auch diese Meldung konnte jedoch
die aufgeschreckten Anleger nicht beruhigen. Mit einem Minus von 20 Dollar und einem aktuellen Kurs von 10 Dollar führt die Firma die Verliererliste eindrucksvoll an.

Mann sollte nur nicht sein ganzes Geld drauf verwetten, daß sie wiederkommt. Ich hoffe aber, daß bald eine neue Meldung kommt.
Hohes Risiko mit hohen Gewinnmöglichkeiten.
Ich denke in den nächste Wochen werden wir sehen, ob sie wieder gen Norden geht. Gestern war ja wohl richtig gut.

mfg Plaste

[Plaste]

Ist das der Grund für die heutige Steigerung?
Jetzt sag bloß keiner, "normale Gegenreaktion"
Übrigens kann das bitte mal jemand sinngemäß übersetzen (aber nicht alles, nur das wichtigste)? Wäre echt nett, da die Übersetzungsprogramme ja noch nicht so weit sind.


Frisch von der Homepage:

Datum 13.10.00

Cell Pathways (ticker: CLPA, exchange: NASDAQ) News Release - 13-Oct-2000

New Research Demonstrates Anti-Angiogenic Properties for
SAANDs Despite the Presence of Vascular Growth Stimulators

HORSHAM, Pa.--(BW HealthWire)--Oct. 13, 2000--Indiana University Medical Center
researchers, led by Dr. Christopher Sweeney, have demonstrated that selective apoptotic
antineoplastic drugs (SAANDs) possess antiangiogenic properties that inhibit vascular
endothelial cell proliferation and new blood vessel formation.

This anti-cancer activity is in addition to the drugs` ability to trigger apoptosis, or
programmed cell death, selectively in cancer cells. In laboratory assays, the researchers
tested two of Cell Pathways` (Nasdaq:CLPA) SAANDs, exisulind (Aptosyn(TM)) and a
second-generation compound, CP461. Both drugs, which are currently in human clinical
cancer trials, inhibited the proliferation of human umbilical venous endothelial cells
(HUVECs) and the formation of capillaries in a dose-dependant manner, even in the
presence of vascular growth stimulating factors. Moreover the two SAANDs inhibited
capillary formation at substantially lower doses than were required to inhibit endothelial cell
proliferation. The findings were reported today at the "Angiogenesis in Cancer" meeting of
the American Association for Cancer Research (AACR) in Traverse City, MI.

"Drugs that halt tumor growth by preventing them from forming new blood vessels have been
a promising avenue of research for the discovery of anticancer agents," said Dr. Christopher
Sweeney. "However, the antiproliferative effects of some compounds, like the taxanes, are
inhibited in the presence of growth stimulators such as vascular endothelial growth factor
(VEGF) and bovine fibroblast growth factor (bFGF). In contrast, when tested in cell culture
assays of capillary formation and HUVEC proliferation, exisulind and CP461 both
demonstrated antiangiogenic activity that was not overruled by these vascular growth
stimulating factors. Moreover, CP461 inhibited new blood vessel formation at submicromolar
concentrations, values well below blood levels already achieved by this drug in Phase I
clinical trials. Current research is ongoing to determine if the antiangiogenic effect of CP461
involves cyclic GMP (cGMP)-based mechanisms similar to those responsible for the drug`s
pro-apoptotic activity."

"These exciting results suggest that CP461 may be able to fight cancer simultaneously
preventing the formation of new blood vessels required by the tumor to sustain its growth
and triggering apoptosis or suicide in the cancerous cells," said W. Joseph Thompson,
Ph.D., Cell Pathways` vice president of research. Dr. Thompson noted that Cell Pathways
recently completed Phase I safety studies of CP461 as a single agent and was preparing to
begin single-agent Phase II cancer studies.

In the proliferation assay, the researchers first incubated HUVECs for 48 hours and exposed
them to varying concentrations of exisulind and CP461, both with and without the growth
stimulators VEGF and bFGF. They then measured the viability of the cells. The researchers
found that exisulind inhibited proliferation of the HUVECs by 50% (IC50) at 1000 micromolar
concentrations, both in the presence of and without growth stimulating factors. With and
without stimulation, the IC50 of CP461 for HUVEC proliferation was 20 micromolar. In the
capillary formation assay, the researchers evaluated the ability of stimulated HUVECs to
form capillaries from microcarrier beads placed in a fibrin clot. The IC50 of exisulind and
CP461 in the capillary formation assay was 437 micromolar and 0.5 micromolar,
respectively.

Exisulind (Aptosyn(TM)) and CP461 are the first members of a new class of potential
therapeutic agents called selective apoptotic antineoplastic drugs, or SAANDs, discovered
and under development by Cell Pathways. The company and its collaborators have
previously shown the ability of SAANDs to trigger apoptosis in abnormal cells in over 50
different tumor cell lines, as well as in animal models of a variety of human cancers.
Aptosyn(TM) is under clinical development for preventing or treating precancerous colon
polyps in individuals with familial adenomatous polyposis (FAP), an inherited disease
caused by a defect in the APC gene and the accumulation of beta-catenin in precancerous
cells. Further, Aptosyn(TM) was found to reduce the rise in PSA levels in men with prostate
cancer at risk of recurrence after prostatectomy. Cell Pathways is conducting additional
clinical development of Aptosyn(TM), both as a single agent and in combination with
traditional chemotherapeutic agents against a variety of cancers and precancerous
conditions.

Cell Pathways, Inc., headquartered in Horsham, is a development-stage pharmaceutical
company focused on the research, development and commercialization of novel and unique
compounds to prevent and treat cancer. For additional information on Cell Pathways, Inc.,
visit the company`s Web site at http://www.cellpathways.com.

Certain statements made herein, and oral statements made in respect hereof, constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements are those which express plan, anticipation, intent,
contingency or future development and/or otherwise are not statements of historical fact.
These statements are subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those expressed or implied
in such statements. Such risks and uncertainties relate to, among other factors, the
absence of approved products; history of operating losses; early stage of development; the
costs, delays and uncertainties inherent in basic pharmaceutical research, drug
development, clinical trials and the regulatory approval process, with respect to both the
Company`s current product candidates and its future product candidates, if any;
dependence on the development and market acceptance of Aptosyn(TM) (exisulind) for one
or more significant disease indications; the limitations on, or absence of, the predictive value
of data obtained in laboratory tests, animal models and human clinical trials when planning
additional steps in product development; the uncertainty of obtaining regulatory approval of
any compound for any disease indication; the delay, uncertainty and adversity arising from
the recent action of the FDA in issuing a "not approvable" letter with respect to the New
Drug Application ("NDA") submitted for Aptosyn(TM) (exisulind) for the orphan drug
condition of familial adenomatous polyposis, a rare disease that puts those afflicted at high
risk of developing colon cancer; the uncertainty of the effect of product approval, if achieved,
on the market price of the Common Stock; the timing and scope of any approval which
might be received for any compound for any indication in the future; acceptance by providers
of healthcare reimbursement; the validity, scope and enforceability of patents; the actions of
competitors; dependence upon third parties; product liability; and the need for further
financing. These and other risks are detailed in the Company`s reports filed from time to
time under the Securities Act of 1933 and/or the Securities Exchange Act of 1934, including
the sections entitled "Business," "Risk Factors," "Management`s Discussion and Analysis
of Financial Condition and Results of Operations" and "Other Events" in the Company`s
reports on Form 10-K for the year ended Dec. 31, 1999 and Forms 10-Q and 8-K during
2000 and in such registration statements on Form S-3 as may be filed from time to time.
You are encouraged to read these filings as they are made. They are available over the
Internet from the SEC in its EDGAR database. Given the uncertainties affecting
pharmaceutical companies in the development stage, current and prospective investors are
cautioned not to place undue reliance on any such forward-looking statements, any of which
may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or
other factors. No forward-looking statement can be guaranteed; actual future results may
vary materially. Both forward-looking statements and statements of historic fact must be
understood in the context of the risks referred to above which characterize the Company`s
development stage business. The Company undertakes no obligation to update or revise the
statements made herein or the factors which may relate thereto.

--30--nj/sf*

CONTACT:
Cell Pathways Investor Relations
Patrick T. Mooney, M.D., 215/706-3800 (Investor)
or
J. Kureczka Associates
Joan E. Kureczka, 415/821-2413 (Media)

[Plaste]

New Research Extends Understanding of How SAANDs Trigger
Suicide in Cancerous and Precancerous Cells Via Multiple
Apoptosis Pathways

HORSHAM, Pa.--(BW HealthWire)--Oct. 16, 2000--

Clinical Cancer Research Publication Further Describes Mechanism

of Action for a New Class of Anti-Cancer Drugs

Scientists at Columbia University College of Physicians and Surgeons have reported that a
new drug target, previously identified by their collaborators at Cell Pathways, Inc.
(Nasdaq:CLPA), may affect cancer cell survival by impacting more than one downstream
cellular pathway controlling programmed cell death, or apoptosis.

The drug target described consists of the cyclic GMP phosphodiesterases (cGMP PDE) of
the PDE5 and PDE2 gene families. Exisulind (Aptosyn(TM)) and other compounds in Cell
Pathways` family of selective apoptotic antineoplastic drugs (SAANDs) inhibit these target
cGMP PDEs, which the company and its collaborators have found over-expressed in
cancerous and precancerous cells of the colon, and cancers of the lung, prostate, breast,
bladder and pancreas. This activity leads to the inhibition of growth of a broad variety of
malignant tumor cells in both cell culture and animal models of human cancers.

The new research appears in the October issue of the journal Clinical Cancer Research.
Columbia University scientists led by Dr. Bernard Weinstein, director emeritus of the
Herbert Irving Comprehensive Cancer Center and Dr. Jae-Won Soh and their collaborators at
Cell Pathways co-authored the paper.

Research has shown that the inhibition of these target cGMP PDE proteins triggers a chain
of events that result in the apoptosis of cancerous and precancerous cells, but not normal
ones. Cell Pathways researchers recently reported (Cancer Research July 1, 2000) that
exisulind and other SAANDs induce apoptosis in colon tumor cells by inhibiting the different
forms of cGMP PDE in these cell lines. This results in a sustained increase in cGMP in the
cells and the activation of cGMP-dependent protein kinase (PKG). Increased PKG activity in
cancer cells forces the degradation of beta-catenin, an important regulatory protein that
accumulates in neoplastic cells, thus triggering cell death by apoptosis through well-studied
mechanisms.

"We have expanded those observations by demonstrating that, in addition to beta-catenin,
PKG activation also activates another important apoptosis pathway, the JNK-1 pathway,"
said Dr. Weinstein. "This is an extremely important observation because it indicates that by
inhibiting these cGMP PDEs, multiple downstream pathways that regulate cancer cell
growth are simultaneously affected increasing the likelihood that even cancer cells with
diverse mutations will be killed. Also, CP461 and CP248, which are better inhibitors of
PDE5 and PDE2 than exisulind, may be more potent in activating the JNK-1 pathway and in
their ability to induce apoptosis and inhibit growth of the cancer cells."

"We are very excited about the results of this study, which expand upon our earlier research
findings," said Dr. Rifat Pamukcu, M.D., chief scientific officer and executive vice president
of research and development at Cell Pathways, Inc. "Moreover, an independent group of
investigators at the University of Missouri recently reported results of an animal study, in the
September 15th issue of Cancer Research, demonstrating that the formation of
precancerous intestinal polyps was significantly decreased after the triggering of this
cGMP-mediated pathway. These studies, combined with our previous published research,
substantially validate the use of this cGMP-dependent pathway as an important area for
anti-cancer and cancer chemopreventive drug development."

Apoptosis and SAANDs

Apoptosis is the body`s response to a normal, orderly sequence of biochemical or physical
signals by which damaged or "worn out" cells are eliminated to make way for healthy, new
cells. When the mechanism of apoptosis goes awry, cells continue to multiply and grow
inappropriately, forming a mass of tissue -- a cancerous tumor. In colon cancer, excessive
cell growth occurs as the result of the accumulation of a regulatory protein, beta-catenin,
caused by mutations in the adenomatous polyposis coli (APC) gene.

Cyclic nucleotide PDEs consist of 11 gene families, each having one or more different
members or "isoforms." Each family of PDEs is characterized by their ability to bind and
degrade cyclic AMP (cAMP) and/or cGMP, but differs in their immunological, physical and
kinetic properties. Only a limited number of PDE isoforms are expressed and used by any
single type of cell or tissue to regulate cGMP or cAMP levels. "Pharmaceutical developers
have been studying these enzymes as potential drug targets to modulated cyclic nucleotide
levels in diseases where their levels are important, such as asthma and heart disease," said
Dr. W. Joseph Thompson, vice president of research at Cell Pathways. "Until now, PDE
inhibitors have not been developed as anti-cancer agents. Moreover, the majority of PDE
inhibitors investigated to date do not induce apoptosis in tumor cells. Thus, exisulind and
SAANDs represent a chemical class of unique PDE inhibitors."

Promising Clinical and Pre-Clinical Results

Cell Pathways has demonstrated the ability of exisulind (Aptosyn(TM)) and other SAANDs
to trigger apoptosis in abnormal cells in over 50 different tumor cell lines, as well as in
animal models of a variety of human cancers. Exisulind (Aptosyn(TM)) has demonstrated
clinical activity in preventing or treating precancerous colon polyps in individuals with familial
adenomatous polyposis (FAP), an inherited disease caused by a defect in the APC gene
and the accumulation of beta-catenin in precancerous cells. Further, exisulind
(Aptosyn(TM)) was found to reduce the rise in PSA levels in men with prostate cancer at
risk of recurrence after prostatectomy. Cell Pathways is conducting additional clinical trials
with exisulind (Aptosyn(TM)), both as a single agent and in combination with traditional
chemotherapeutic agents against such cancers and precancerous conditions as prostate,
breast and lung cancer, sporadic colon polyps (a precursor to colon cancer), and Barrett`s
esophagus (a precursor to esophageal cancer). Cell Pathways recently completed Phase IB
safety studies with a second SAAND compound, CP461, in cancer patients. Other Cell
Pathways compounds with greater cGMP PDE inhibitory and pro-apoptotic activity, such as
CP248, are in preclinical development.

The research study reported in Clinical Cancer Research was funded by Cell Pathways, Inc.

Cell Pathways, Inc., headquartered in Horsham, is a development-stage pharmaceutical
company focused on the research, development and commercialization of novel and unique
medications to prevent and treat cancer. For additional information on Cell Pathways, Inc.,
visit the company`s Web site at http://www.cellpathways.com.

Certain statements made herein, and oral statements made in respect hereof, constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements are those which express plan, anticipation, intent,
contingency or future development and/or otherwise are not statements of historical fact.
These statements are subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those expressed or implied
in such statements. Such risks and uncertainties relate to, among other factors, the
absence of approved products; history of operating losses; early stage of development; the
costs, delays and uncertainties inherent in basic pharmaceutical research, drug
development, clinical trials and the regulatory approval process, with respect to both the
Company`s current product candidates and its future product candidates, if any;
dependence on the development and market acceptance of Aptosyn(TM) (exisulind) for one
or more significant disease indications; the limitations on, or absence of, the predictive value
of data obtained in laboratory tests, animal models and human clinical trials when planning
additional steps in product development; the uncertainty of obtaining regulatory approval of
any compound for any disease indication; the delay, uncertainty and adversity arising from
the recent action of the FDA in issuing a "not approvable" letter with respect to the New
Drug Application ("NDA") submitted for Aptosyn(TM) (exisulind) for the orphan drug
condition of familial adenomatous polyposis, a rare disease that puts those afflicted at high
risk of developing colon cancer; the uncertainty of the effect of product approval, if achieved,
on the market price of the Common Stock; the timing and scope of any approval which
might be received for any compound for any indication in the future; acceptance by providers
of healthcare reimbursement; the validity, scope and enforceability of patents; the actions of
competitors; dependence upon third parties; product liability; and the need for further
financing. These and other risks are detailed in the Company`s reports filed from time to
time under the Securities Act of 1933 and/or the Securities Exchange Act of 1934, including
the sections entitled "Business," "Risk Factors," "Management`s Discussion and Analysis
of Financial Condition and Results of Operations" and "Other Events" in the Company`s
reports on Form 10-K for the year ended December 31, 1999 and Forms 10-Q and 8-K
during 2000 and in such registration statements on Form S-3 as may be filed from time to
time. You are encouraged to read these filings as they are made. They are available over the
Internet from the SEC in its EDGAR database. Given the uncertainties affecting
pharmaceutical companies in the development stage, current and prospective investors are
cautioned not to place undue reliance on any such forward-looking statements, any of which
may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or
other factors. No forward-looking statement can be guaranteed; actual future results may
vary materially. Both forward-looking statements and statements of historic fact must be
understood in the context of the risks referred to above which characterize the Company`s
development stage business. The Company undertakes no obligation to update or revise the
statements made herein or the factors which may relate thereto.

--30--nj/sf*

[Plaste]

Exisulind and CP461 Enhance the Growth Inhibitory Effects of
Chemotherapeutic Agents On Human Lung Cancer Cell Lines

HORSHAM, Pa.--(BUSINESS WIRE)--Oct. 16, 2000--

Research Presented at European Cancer Conference Details Additive

and Synergistic Effects of SAANDs Compounds

Research led by Joan H Schiller, M.D. of the University of Wisconsin and collaborators from
Cell Pathways, Inc. (Nasdaq:CLPA) shows that exisulind (Aptosyn(tm)) and CP461 both
enhance the anti-proliferative effects of chemotherapeutic drugs on human non-small cell
lung cancer cell lines. The two selective apoptotic antineoplastic agents (SAANDs), when
combined with gemcitabine, vinorelbine, or irinotecan, inhibited the growth of two cell lines of
different malignant potential more effectively than could be achieved by each
chemotherapeutic agent alone. Moreover, CP461 demonstrated single agent activity against
the lung cancer cell lines that was comparable to that of chemotherapeutic agents alone.
The research is being presented today at the European Society for Medical Oncology
(ESMO) meeting in Hamburg, Germany.

Dr. Schiller said, "Individually, each chemotherapeutic agent and SAAND showed
dose-dependent inhibition of tumor growth, with CP461 inhibiting cell growth as effectively as
single-agent chemotherapy. When CP461 or exisulind was combined with gemcitabine,
vinorelbine, or irinotecan, however, the combination of SAAND and chemotherapeutic drug
resulted in additional growth inhibitory effects."

"These laboratory results provide the rationale for several human clinical studies to
investigate combinations of CP461 or exisulind plus chemotherapy in non-small cell lung
cancer patients," said Joseph D. Purvis, M.D., Cell Pathways vice president of clinical
development. "In addition, based on this and other research, we are preparing to initiate
single-agent studies of CP461 in early 2001."

Exisulind (Aptosyn(tm)) and CP461 are the first members of a new class of potential
therapeutic agents called selective apoptotic antineoplastic drugs, or SAANDs, which have
been discovered and are under development by Cell Pathways, Inc. The company and its
collaborators have previously shown the ability of SAANDs to trigger apoptosis in abnormal
cells in over 50 different tumor cell lines, as well as in animal models of a variety of human
cancers. Aptosyn(tm) is under clinical development for preventing or treating precancerous
colon polyps in individuals with familial adenomatous polyposis (FAP), an inherited disease
caused by a defect in the APC gene and the accumulation of beta-catenin in precancerous
cells. Further, Aptosyn(tm) was found to reduce the rise in PSA levels in men with prostate
cancer at risk of recurrence after prostatectomy. Cell Pathways is conducting additional
clinical development of Aptosyn(tm), both as a single agent and in combination with
traditional chemotherapeutic agents against a variety of cancers and precancerous
conditions.

Cell Pathways, Inc., headquartered in Horsham, Pa., is a development-stage
pharmaceutical company focused on the research, development and commercialization of
novel and unique compounds to prevent and treat cancer. For additional information on Cell
Pathways, Inc., visit the company`s website at http://www.cellpathways.com

Certain statements made herein, and oral statements made in respect hereof, constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. Such statements are those which express plan, anticipation, intent,
contingency or future development and/or otherwise are not statements of historical fact.
These statements are subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those expressed or implied
in such statements. Such risks and uncertainties relate to, among other factors, the
absence of approved products; history of operating losses; early stage of development; the
costs, delays and uncertainties inherent in basic pharmaceutical research, drug
development, clinical trials and the regulatory approval process, with respect to both the
Company`s current product candidates and its future product candidates, if any;
dependence on the development and market acceptance of Aptosyn(tm) (exisulind) for one
or more significant disease indications; the limitations on, or absence of, the predictive value
of data obtained in laboratory tests, animal models and human clinical trials when planning
additional steps in product development; the uncertainty of obtaining regulatory approval of
any compound for any disease indication; the delay, uncertainty and adversity arising from
the recent action of the FDA in issuing a "not approvable" letter with respect to the New
Drug Application ("NDA") submitted for Aptosyn(tm) (exisulind) for the orphan drug condition
of familial adenomatous polyposis, a rare disease that puts those afflicted at high risk of
developing colon cancer; the uncertainty of the effect of product approval, if achieved, on the
market price of the Common Stock; the timing and scope of any approval which might be
received for any compound for any indication in the future; acceptance by providers of
healthcare reimbursement; the validity, scope and enforceability of patents; the actions of
competitors; dependence upon third parties; product liability; and the need for further
financing. These and other risks are detailed in the Company`s reports filed from time to
time under the Securities Act of 1933 and/or the Securities Exchange Act of 1934, including
the sections entitled "Business," "Risk Factors," "Management`s Discussion and Analysis
of Financial Condition and Results of Operations" and "Other Events" in the Company`s
reports on Form 10-K for the year ended December 31, 1999 and Forms 10-Q and 8-K
during 2000 and in such registration statements on Form S-3 as may be filed from time to
time. You are encouraged to read these filings as they are made. They are available over the
Internet from the SEC in its EDGAR database. Given the uncertainties affecting
pharmaceutical companies in the development stage, current and prospective investors are
cautioned not to place undue reliance on any such forward-looking statements, any of which
may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or
other factors. No forward-looking statement can be guaranteed; actual future results may
vary materially. Both forward-looking statements and statements of historic fact must be
understood in the context of the risks referred to above which characterize the Company`s
development stage business. The Company undertakes no obligation to update or revise the
statements made herein or the factors which may relate thereto.

--30--cs/sf*

CONTACT:
Cell Pathways Investor Relations
Patrick T. Mooney, M.D., 215/706-3800
or
J. Kureczka Associates (Media)
Joan E. Kureczka, 415/821-2413

[Plaste]

Mittwoch 18. Oktober 2000, 10:21 Uhr

Pharma & Biotech Licensing and Deal-Making Summit to be Attended by
Global Rx, Licensing and Business Development Executives, November 2-3,
in New Je

New York (ots-PRNewswire) - Starting with Salomon Smith Barney`s Head of Global Health Care, David MacCallum, the 4th
International Pharma & Biotech Licensing and Deal Making Summit in Long Branch New Jersey, 2-3 November will profile a
wide range of recent major deals and unveil upcoming business opportunities reports Strategic Research Institute.

Other featured speakers include top executives from Bristol - Myers Squibb, SmithKline Pharmaceuticals, Eli Lilly & Company,
Hoffmann - La Roche, Elan Pharmaceuticals, Millennium Pharmaceuticals, Wyeth Ayerst Pharmaceuticals, Chase H & Q, KPMG,
and Vertex Pharmaceuticals.

Among the companies already attending the conference are:

Abbott Labs (Frankfurt: 850103.F - Nachrichten)

Advanced Medicine

Affymax Research

Akin Gump Strauss Hauer & Feld

Amgen

Aronex

Astrazeneca

Aeterna Labs

Alza Corporation

Aurigin Systems

Aventis Pasteur Baxter Healthcare Biogen, Inc

BioNebraska Inc

Bio-Technical Resources

Bristol-Myers Squibb (Frankfurt: 850501.F - Nachrichten)

Cell Pathways (Frankfurt: 917206.F - Nachrichten) Inc

Chase H&Q,

DAS, Inc

Debiopharm SA

Discovery Labs

Eastman Chemical

Elan Corporation

Eli Lilly & Co.

Ethicon Inc

Genetronics, Inc

Geron Corporation

Glaxo Welcome, Inc

Graffinity Pharma

Design GmbH

Guilford Pharma

Hoffmann-La Roche

KPMG LLP

Lavipharm Labs

Licent Capital

Lorusso & Loud

MacroMed, Inc

McKinsey & Company

Meiji Seika, USA

Meridian Medical Technologies

Meristem Therapeutics

Merlin Technologies

Metaphore Pharmaceuticals

Millennium Pharmaceuticals

Muro Pharma

NexMed USA, Inc

Ortho McNiel

PA Consulting

Patent & License Exchange

PAREXEL

Pharmaventures UK

Powderject Technologies

Pricewaterhouse-Coopers

Professional Detailing, Inc

Protiveris Inc

QED Technologies

Reha Medical

Roche Molecular Systems

Sangamo Biosciences

Salomon Smith Barney

Smithkline Beecham Pharmaceuticals

Tanner & Co LLC

TechEx

Triangle Pharmaceuticals

Thyreos Corporation

Valentis, Inc

Vertex Pharmaceuticals

VitaGen Incorporated

Wyeth-Ayerst Laboratories

To register, please call 1-800-599-4950. The registration fee is $1395.

The full agenda is available at http://www.srinstitute.com/cs162 or by calling Sonali Pathirana at 800-599-4950, x248.

ots Original Text Service: Strategic Research Institute Internet: http://recherche.newsaktuell.de

Contact: Sonali Pathirana of Strategic Research Institute, (USA) 212-967-0095, ext. 248, or http://www.srinstitute.com/cs162

Web site: http://www.srinstitute.com/cs162

[Plaste]

Wednesday October 18, 12:20 pm Eastern Time

Cell Pathways loss widens

NEW YORK, Oct 18 (Reuters) - Cell Pathways Inc. (NasdaqNM:CLPA - news) on Wednesday said its losses widened about
67 percent in the third quarter due to rising research and development costs, but the results were better than Wall Street had
expected.

The company posted a net loss of $7.5 million, or 27 cents per diluted share, compared with a loss of $4.5 million, or 18 cents
per diluted share, a year earlier. Common shares outstanding were up 13 percent.

Wall Street analysts on average had predicted the Horsham, Pa.-based company would lose 29 cents per share, according to First Call/Thomson Financial.

Research and development expenses rose about 67.5 percent from a year earlier, to $5.9 million, while general and administrative expenses were up 68.4 percent to
$2.1 million. Research and development costs surged primarily as a result of research on the company`s lead product, Aptosyn, to treat colon cancer.

Shares of Cell Pathways were down 3/16 to $7-13/16 near midday.


Hier ein Übersetzungsversuch:
Auf Deutsch



Mittwoch Oktober 18, 12:20 P.M. östliche ZeitZelle Bahnverlust verbreitertNew York, Okt 18
(Reuters) - Cell Pathways Inc. (NasdaqNM:CLPA -Nachrichten) am Mittwoch, der seine
Verluste besagt ist, verbreiterteungefähr 67 Prozent im dritten Trimester wegen der
steigendenForschung und Entwicklung Kosten, aber die Resultate waren besser, alsWall
Street erwartet hatte.Die Firma gab einen Reinverlust von $7,5 Million oder 27 Cents pro
denverdünnten Anteil bekannt, verglichen mit einem Verlust von $4,5Million oder 18 Cents pro
verdünnten Anteil, ein Jahr früher. Dieallgemeinen ausgegebenen Aktien waren herauf 13
Prozent.Wall Street, die Analytiker auf Durchschnitt das Horsham,Pa.-basedfirma
vorausgesagt hatten, würde 29 Cents pro Anteilverlieren, entsprechend erstem finanziellem
Call/Thomson.Forschung und Entwicklung Unkosten stiegen ungefähr 67,5 Prozent vonein
Jahr früher, bis $5,9 Million, während allgemeine undVerwaltungskosten herauf 68,4 Prozent
bis $2,1 Million waren.Forschung und Entwicklung Kosten schwankten
hauptsächlichresultierend aus Forschung auf dem Produkt Leitung der Firma, Aptosyn,um
Doppelpunktkrebs zu behandeln.Anteile der Zelle Bahnen waren hinunter 3/16 bis $7-13/16
nahe Mittag.

[puhvogel]

Am liebsten mag ich die Stelle mit dem "Doppelpunktkrebs"

[Plaste]

Immer wieder lustig diese Übersetzungsprogramme.

mfg Plaste

[Plaste]

juchu schrieb dazu am 22.10.00:

Cell Pathways (CLPA) gab sein Quartalsergebnis bekannt. Das Unternehmen erwirtschaftete in den
vergangenen 3 Monaten einen Verlust von 7,5 Millionen US$ oder $ 0,27/Aktie. Noch im Jahr zuvor lag
der Vlerust bei 4,5 Millionen US$ oder $ 0,18/Aktie. Die Ausgaben für Forschung und Entwicklung
lagen im 3. Quartal bei 5,9 Millionen US$, was einem Anstieg von 67,5 % oder 2,4 Millionen US$
gegenüber der Vergleichsperiode des Vorjahres entspricht. Das Unternehmen erzielt bislang keine
Umsätze.

[ani]

Hallo Leute hat jemand noch diese Aktien, und was ratet ihr ?

[Quix99]

Hi ani !
hab noch ein paar davon, allerdings unter 1% Depotanteil.
Laß ich dauerhaft liegen, wenn Cell Pathways in den kommenden Monaten doch noch die Zulassung für das damals abgelehnte Medikament erhält steht der Kurs auch wieder bei 20 bis 30 Euro.
Allerdings sollte man bei solchen Risikopapieren wie gewohnt nur kleine Positionen halten.
Grüße Quix

[ani]

Hi Quix99, ich glaube wir sind die Einzigen die daran glauben

[Preacher]

Stimmt nicht!
Auch ich glaube noch an diese Aktie, obwohl in den letzten Tagen nochmals arg gebeutelt. Ich werde jetzt nochmals nachkaufen und gehe fest davon aus, dass Cell Pathways es schaffen wird.

[Quix99]

@Ani&Preacher
Seit ihr noch dabei ?
Cell Pathways hat in den letzten Tagen die 38Tagelinie nach oben durchbrochen. Der Umsatz könnte ein wenig zulegen, in den USA läufts besser.
Grüße uix

[Preacher]

Hallo Quix99!
Ich bin noch dabei und habe Ende letzten Jahres kräftig zu 4,50 nachgelegt. Ich bin derzeit immer noch von Aptosysn überzeugt, glaube jedoch nicht an einen schnellen überproportionalen Anstieg von CLPA.
Immerhin, es scheint keine neuen schlechten Nachrichten zu geben. Ich wünsche uns gute Kurse und kräftige Gewinne.
Gruß Preacher
PS: Ich wollte mich bei Cellpathways auf der homepage in den Newsverteiler aufnehmen lassen. Als Bestätigung bekomme ich immer nur eine Fehlermeldung. Kann mir jemand helfen?

[Preacher]

Hallo an die CLPA-Gemeinde:
Endlich zieht der Kurs wieder ein wenig an.
Ob das mit der letzten News von heute zu hat?

Cell Pathways (CLPA) Initiates Phase III Clinical Trial In
Non-Small Cell Lung Cancer
Cell Pathways, Inc. (Nasdaq:CLPA - news) today announced the
initiation of a Phase III study in 600 patients with advanced non-small
cell lung cancer (NCSLC) refractory to standard platinum containing
combination chemotherapy. The double-blind, placebo controlled
study will evaluate Aptosyn(TM) (exisulind), Cell Pathways` lead
investigational drug, in combination with Taxotere® (docetaxel) versus
Taxotere alone. The primary endpoint of the study is increased survival
(overall and one-year) of patients receiving the Aptosyn/Taxotere
combination compared to Taxotere alone.

Soweit ich das verstehe, ist mit dem Ergebnis der Studie erst in einem Jahr zu rechnen.
Trotzdem heute ein schönes Kursplus.
Gute Kurse allen, die an CLPA glauben.

[Quix99]

Hallo !
Bin noch dabei !

[OnkelDilbert]

Ich auch!!
Die Studie soll übrigens nachweisen, dass die Substanz Aptosyn auch in der Therapie von Krebserkrankungen einsetzbar ist, also nicht nur in der Vorbeugung von Tumoren.
Das ist ein neuer Ansatz bei CLPA. Bin mal gespannt, was sich da noch so tut. CLPA hat ja in der letzten Zeit einige kompetente Leute dazugeholt und ausserdem das Netzwerk zu den Krebszentren in den USA ausgebaut.
Ich werde jedenfalls den Kurs täglich verfolgen.
Gruß, O.D. :-))

[FLOTSAM_AND_JETSAM_US]

langsam gehts mit CLPA wieder nach oben

Wednesday May 23, 8:00 am Eastern Time

Newly Identified Target in Pancreatic Cancer Cells May Lead to Targeted Therapy by Selective Apoptotic Anti-Neoplastic Drugs

Cell Pathways` CP461 Targets Over-Expressed Cyclic GMP Phosphodiesterase Leading to Pancreatic Cancer Cell Death
ATLANTA--(BW HealthWire)--May 23, 2001-- New laboratory research provides evidence that a novel anti-cancer drug target, a cyclic GMP phosphodiesterase 5 (PDE5), originally identified by scientists from Cell Pathways, Inc. (Nasdaq:CLPA - news) and their collaborators, was strongly over-expressed in 77% of human pancreatic carcinomas examined in this study. At the same time, the research shows little expression of that enzyme in normal pancreatic tissues. Moreover, laboratory research with CP461, an investigational drug under development by Cell Pathways, Inc. that targets the cGMP PDEs over-expressed in cancers, demonstrated that drug`s ability to induce apoptosis or cellular suicide in two human pancreatic cancer cell lines, including cells expressing ras mutations that commonly lead to drug resistance.

The research was presented today at the annual meeting of the American Gastroenterological Association by scientists from Cell Pathways in collaboration with investigators from Fox Chase Cancer Center (Philadelphia, PA) and Indiana University (Indianapolis, IN).

The investigators studied the expression of PDE5 in pancreatic cancer specimens from 13 patients by assessing the Labeling Intensity (LI) using antibodies specific to PDE5. The LI grading in samples ranged from none (0) to very strong (3). PDE5 was strongly expressed in pancreatic cancers from 10 of 13 patients (LI= 2.0 +/- 0.2) in contrast to weak expression in normal pancreatic tissue obtained from the same patients (acini and islets (LI= 0.5 +/- 0.3, p less than or equal to 0.01) or ductal epithelium (1.2 +/- 0.2, p less than or equal to 0.05)). There was no correlation between PDE5 expression and ras mutational status. To further assess the potential role of CP461 in the treatment of pancreatic cancer, the ability of CP461 to induce apoptosis was quantified in the PaCa2 and BxPC3 pancreatic cancer cell lines. CP461 induced apoptosis in the PaCa2 and BxPC3 cell lines at EC(50) of 0.8 and 1.4 uM, respectively. The PaCa2 cell line harbors a ras mutation whereas the BxPC3 cell line has a normal ras gene.

``Phase I clinical study results reported last week at American Society of Clinical Oncology (ASCO) showed that CP461 is rapidly absorbed, and that doses higher than 200 mg/day achieved plasma concentrations of drug that exceeded the concentrations required to induce apoptosis in laboratory cultured cancer cells, including these two pancreatic cancer cell lines,`` said Rifat Pamukcu, M.D., Cell Pathways` chief scientific officer. ``Based on the identification of the cGMP PDE target for CP461 in these pancreatic cancers, we plan to initiate Phase I trials investigating combination therapies of conventional chemotherapeutic agents with CP461. One of the planned studies will evaluate CP461 with gemcitabine, a chemotherapeutic agent currently used as first-line therapy in pancreatic cancer. Pending the safety results with this combination, we may consider additional clinical trials with a goal toward registration of the drug in combination with gemcitabine.``

CP461 and exisulind (Aptosyn(TM)) are both members of a new class of compounds called SAANDs that selectively trigger programmed cell death, or apoptosis, in precancerous and cancerous cells but not normal cells. Research by Cell Pathways and others has demonstrated that these drugs achieve their pro-apoptotic effect by inhibiting specific cyclic GMP phosphodiesterases, thus allowing death of the abnormal cells to occur through apoptotic pathways. Both compounds are in human clinical development as potential treatments for a variety of cancers. Among the ongoing trials is a 600 patient, multi-center Phase III study of Aptosyn(TM) and Taxotere® in patients with advanced non-small cell lung cancer (NSCLC), initiated in March 2001. CP461 is entering pilot Phase II trials in cancer patients as a single agent. Phase I trials of CP461 in combination with other currently used chemotherapeutic agents are planned.

Cell Pathways, Inc., headquartered in Horsham, Pennsylvania, is a development stage pharmaceutical company focused on the research, development and commercialization of novel and unique medications to prevent and treat cancer. For additional information on Cell Pathways, Inc., visit the company`s web site at http://www.cellpathways.com.

[KingsX]

es tut sich was im August....

Cashposition reicht noch bis zum 1. Quartal 2003, bis
dahin müßte die Zulassung für das erste Medikament da sein..